- |||||||||| Lantus (insulin glargine) / Sanofi
Clinical, Journal: Time Lag and Accuracy of Continuous Glucose Monitoring During High Intensity Interval Training in Adults with Type 1 Diabetes. (Pubmed Central) - Feb 16, 2020
Seventeen participants with T1D, using multiple daily injections (MDI) with basal insulin glargine 300 U/mL (Gla-300), completed four fasted HIIT sessions over 4 weeks while wearing a Dexcom rtCGM G4 Platinum system. During HIIT and early recovery, there is an increase in lag time and a related decline in accuracy of Dexcom rtCGM G4, compared to pre-exercise and later recovery, in patients with T1D using MDI.
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway. (Pubmed Central) - Feb 7, 2020
Follow-on insulin products approved through the 505(b)(2) pathway are supported by robust efficacy and safety data. As new follow-on insulins are approved and the regulatory change that will occur with these products in 2020 approaches, formulary decisions and clinical policies (eg, substitution) will continue to be revisited.
- |||||||||| Soliqua 100/33 (lixisenatide + insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Journal: Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia. (Pubmed Central) - Feb 7, 2020
By Week 30, iGlarLixi improved all GV parameters from baseline with no increased hypoglycaemia risk. Significant improvements were observed in SMPG, SD of SMPG, HBGI, AUCn, MAG, and MAGE compared with iGlar, and in SMPG, HBGI, and AUCn, compared with Lixi.
- |||||||||| metformin / Generic mfg., Lantus (insulin glargine) / Sanofi, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_3059;
His regimen included basal insulin and recent transition to empagliflozin due to severe GI intolerance with metformin use...Upon resolution of his acidosis and normalization of the anion gap he was switched to subcutaneous Insulin Glargine and Lispro...It is also important to educate patients about this condition, mostly notable in the first two months of starting the medication, to recognize the concerning symptoms and precipitating factors like dehydration, improper insulin dosing, low calorie diet, alcohol, infection, surgery. An acceptable alternative to SGLT-2i can be glucagon like peptide receptor (GLP- 1) agonists, also associated with good cardiovascular outcomes.
- |||||||||| Lantus (insulin glargine) / Sanofi
Acute Diabetic Ketoacidosis in Patient with 17q12 Deletion Syndrome. (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_3054;
This is the first report of 17q12 deletion syndrome/MODY5 presenting with DKA and supports the concept that a presentation of DKA does not exclude MODY. Identifying syndromal features and thorough laboratory and genetic evaluation are vital for establishing correct diagnosis and ongoing care.
- |||||||||| metformin / Generic mfg., Lantus (insulin glargine) / Sanofi
Type 2 Diabetes Management in the Context of Smith-Magenis Syndrome: Case Report (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2692;
This case describes a patient managed for metabolic dysfunction in conjunction with a rare microdeletion disorder causing neurobehavioral disturbance with disrupted circadian sleep-wake patterns. The most difficult aspects of diabetes management included difficulty implementing lifestyle modifications to control the patient's hyperglycemia.
- |||||||||| metformin / Generic mfg., Lantus (insulin glargine) / Sanofi
Pancreatic Cancer in Longstanding Diabetes (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2680;
Regarding her T2DM, she was diagnosed 15 years ago and prior to the last month, her glucose had been well controlled on Metformin and Glipizide, never requiring Insulin...During her admission, her glucose continued to range from 178-315 even though she was on Lantus 12 units nightly and an Insulin Sliding Scale before meals...Conclusion Unexplained elevation in HA1C should prompt clinicians to run a differential diagnosis of factors that can induced hyperglycemia. This case highlights the importance of recognizing pancreatic malignancy as a possible cause of worsening hyperglycemia in T2DM.
- |||||||||| metformin / Generic mfg., Lantus (insulin glargine) / Sanofi, donepezil / Generic mfg.
Was Metformin the Culprit for This Lactic Acidosis? (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2678;
Conclusion Metformin is contraindicated in patients with mitochondrial disease and diabetes due to the predisposition for lactic acidosis. This is not part of the current package inserts for prescribers and patients- and we strongly recommend inclusion of this language.
- |||||||||| Fournier's Gangrene and Diabetic Ketoacidosis Caused by Canagliflozin (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2677;
Approximately 1 month prior, sitagliptin and canagliflozin were added to her regimen due to poor glycemic control on metformin (HbA1c 9.8%)...She was discharged with a urinary catheter, vacuum dressing, colostomy with instructions to start insulin glargine 18U and discontinue the oral anti-diabetic medications...In light of the FDA's warnings and the growing popularity of SGLT2 inhibitor therapy it is important to be mindful of their more serious and potentially fatal complications. It is also important to promptly terminate SGLT2 inhibitors when harmful adverse effects are suspected to prevent further progression.
- |||||||||| Lantus (insulin glargine) / Sanofi
Pituitary Hyperplasia Due to Uncontrolled Primary Hypothyroidism: Case Series and Literature Review. (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2205;
She was treated with insulin glargine 20U qd, and levothyroxine 200 mcg/day...Cabergoline was started without any clinical improvement...She was previously treated with hydrocortisone 25mg/day, fludrocortisone 0.1mg/day, and levothyroxine 200mcg/day... We presented three young women, with autoimmune hypothyroidism, who developed pituitary hyperplasia and responded to proper hormonal replacement normalizing pituitary size.
- |||||||||| Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Unusual Presentation of Diabetic Ketoacidosis Associated with Hypernatremia in Adult Patient (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1957;
When there is marked osmotic diuresis, DKA may present with a normal or even elevated serum Na concentration, despite a markedly elevated serum BG. To best of our knowledge, this is the second case to report an unusual DKA presenting with hypernatremia in adult patient.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, tacrolimus / Generic mfg., Lantus (insulin glargine) / Sanofi
A Case of Hyperglycemia in Post Pancreas Transplant Patient-Is It Insulin Deficiency or Insulin Resistance (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1950;
His immunosuppressant (IS) medications were tacrolimus, mycophenolate and prednisone...He was started on insulin degludec 24 units daily, which was quickly tapered to 8 units daily due to hypoglycemia...Once the acute stress resolved, his insulin dose needs reduced significantly, tapering down to insulin glargine 5 units daily...This scenario was most consistent with hyperglycemia due to insulin resistance and subsequent relative insulin deficiency during stress, with continued PTx function. This illustrates the importance of detailed assessment and personalized treatment in patients with post-PTx hyperglycemia.
- |||||||||| Lantus (insulin glargine) / Sanofi
Rare Case of 48 XXYY Syndrome with Suspected Type 1 Diabetes Mellitus (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1944;
There are few case reports describing the association of type 2 DM with this syndrome. Our patient's low BMI, low insulin and C-peptide with hyperglycemia indicate type 1 DM, although the absence of DKA in the setting of noncompliance suggests residual beta cell function or maturity onset diabetes of the young (MODY).
- |||||||||| Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
An Unusual and Enigmatic Etiology for Diabetic Ketoacidosis: Safety Needles (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1936;
Therefore, appropriate administration must be taught to the patient, including perpendicular insertion of the needle into the subcutaneous tissue and ensuring a more firm surface by injecting into a lifted skin fold. Legislation in the US has been passed requiring safety-engineered devices when feasible.In situations where the safety-engineered devices can impair effectiveness or cause harm, alternative approaches can be utilized, including insulin syringes or self-administration of insulin along with safe work procedures (1).
- |||||||||| Lantus (insulin glargine) / Sanofi, Januvia (sitagliptin) / Merck (MSD), semaglutide SC once-daily (NN9536) / Novo Nordisk
Efficacy And Safety Of Semaglutide By Baseline BMI In SUSTAIN 1–5 And 7 () - Feb 2, 2020 - Abstract #QDEM42020QDEM_43;
The estimated treatment differences in mean HbA1c (%) for semaglutide vs placebo or active comparators do not appear to be influenced by baseline BMI. Semaglutide had an acceptable safety profile in all BMI subgroups.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
Clinical, PK/PD data, Review, Journal: Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) a review of evidence and clinical interpretation. (Pubmed Central) - Feb 1, 2020
Compared with earlier insulin analogues, second-generation basal insulins have improved pharmacokinetic/pharmacodynamic profiles that translate into clinical benefits, primarily reduced nocturnal-hypoglycaemia risk. Additional head-to-head comparisons of insulin degludec and insulin glargine 300 U/mL at bioequivalent doses, utilising continuous glucose monitoring and/or real-world evidence, are required to elucidate the differences in their pharmacological and clinical profiles.
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Combined Insulin and GLP-1 Receptor Agonists: Simplifying Treatment or Adding Obstacles? (Pubmed Central) - Jan 30, 2020
With the availability of these agents, concerns with transitions of care arise due to multiple vulnerabilities in reconciling these agents throughout the inpatient admission and discharge process. Provider awareness of the availability and dosing of insulin glargine/lixisenatide and insulin degludec/liraglutide is essential to reduce errors in the medication reconciliation process.
- |||||||||| Lantus (insulin glargine) / Sanofi
Review, Journal, Combination therapy: Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. (Pubmed Central) - Jan 25, 2020
FRCs have demonstrated enhanced glycemic control compared with their constituent components alone, comparable risk of hypoglycemia compared with basal insulin alone, and better tolerability compared with the GLP-1RA component alone due to the slower titration. In this article, we discuss the advantages of FRCs over multiple daily injections, present case studies of typical patients who could benefit from FRC therapy, and outline practical considerations for the initiation of FRC therapy in clinical practice.Funding Sanofi.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
Clinical, Journal: Insulin glargin vs. Insulin degludec bei Patienten mit Nierenfunktionsstörung. (Pubmed Central) - Jan 22, 2020
Optimal SMBG frequency in youth using or not using insulin, and whether less frequent SMBG is a marker for overall worse self-care, require further study. No abstract available
- |||||||||| Lantus (insulin glargine) / Sanofi, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Journal: National trends in prescription drug expenditures and projections for 2019. (Pubmed Central) - Jan 21, 2020
These estimates are at the national level. Health-system pharmacy leaders should carefully examine local drug utilization patterns to determine their own organization's anticipated spending in 2019.
- |||||||||| Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
Enrollment closed, Trial primary completion date: GLITTER 1: Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (clinicaltrials.gov) - Jan 21, 2020
P3, N=550, Active, not recruiting,
Health-system pharmacy leaders should carefully examine local drug utilization patterns to determine their own organization's anticipated spending in 2019. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2019 --> Feb 2020
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
Journal: Long-Acting Basal Insulins: A Review of the More Recently Approved Agents. (Pubmed Central) - Jan 18, 2020
Both insulin glargine U-300 and insulin degludec have been compared with insulin glargine U-100 and have demonstrated longer durations of action, as well as lower rates of hypoglycemia. This review discusses the Food and Drug Administration-approved long-acting insulins with a focus on recently approved agents and their efficacy and safety compared with the first long-acting basal insulins.
- |||||||||| Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
Enrollment closed, Trial primary completion date: GLITTER 2: Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (clinicaltrials.gov) - Jan 18, 2020
P3, N=550, Active, not recruiting,
This review discusses the Food and Drug Administration-approved long-acting insulins with a focus on recently approved agents and their efficacy and safety compared with the first long-acting basal insulins. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2019 --> Feb 2020
- |||||||||| Lantus (insulin glargine) / Sanofi
precio lantus? (Twitter) - Jan 17, 2020
- |||||||||| metformin / Generic mfg., Lantus (insulin glargine) / Sanofi
Review, Journal: Body Weight Considerations in the Management of Type 2 Diabetes. (Pubmed Central) - Jan 17, 2020
Dipeptidyl peptidase-4 inhibitors and fixed-ratio insulin/GLP-1 RA combination therapies (IDegLira, iGlarLixi) appear to be weight-neutral...Patients are often overtitrated on basal insulin, resulting in an increased risk of hypoglycemia and weight gain without achieving glycemic goals. Given these observations, the effects of antihyperglycemia agents on weight should be considered when individualizing T2D therapy.Funding: Sanofi US, Inc.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Trial completion date, Trial primary completion date: Liraglutide Hospital Discharge Trial (clinicaltrials.gov) - Jan 15, 2020
P4, N=330, Recruiting,
Given these observations, the effects of antihyperglycemia agents on weight should be considered when individualizing T2D therapy.Funding: Sanofi US, Inc. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
|
